1887

Abstract

Summary

The optimum rabbit ileal loop (RIL) reacting doses of the new cholera toxin (NCT) produced by cholera toxin gene-negative (CT) strain X-392 and of the enterotoxin produced by cholera toxin gene-positive (CT) strain 569B of Ol were found to be 32 μg and 22 μg respectively. Production of NCT by the CT strain, in addition to CT, was confirmed by in-vivo neutralisation tests. Anti-569B-enterotoxin neutralised the optimum RIL reacting activity of NCT completely at 1 in 16 dilution, whereas the activity of 569B enterotoxin was only partially neutralised (44%) by anti-NCT. Similarly, partial neutralisation (66%) was observed when purified anti-CT was mixed with 569B enterotoxin. Therefore, the fluid accumulation produced in the RIL by 569B enterotoxin was the combined effect of both CT and NCT. No antigenic relationship between NCT and CT could be demonstrated in gel-diffusion tests.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/00222615-32-1-33
1990-05-01
2022-09-30
Loading full text...

Full text loading...

/deliver/fulltext/jmm/32/1/medmicro-32-1-33.html?itemId=/content/journal/jmm/10.1099/00222615-32-1-33&mimeType=html&fmt=ahah

References

  1. Holmgren J, Lonnroth I, Ouchterlony O. Immunochemical studies of two cholera toxin containing standard culture filtrate preparations of Vibrio cholerae. Infect Immun 1971; 3:747–755
    [Google Scholar]
  2. Sanyal S C, Alam K, Neogi P K B, Huq M I, Al-Mahmud K A. A new cholera toxin. Lancet 1983; 1:1337
    [Google Scholar]
  3. Sanyal S C, Neogi P K B, Alam K, Huq M I, Al-Mahmud K A. A new enterotoxin produced by Vibrio cholerae Ol. J. Diarrhoeal Dis Res 1984; 2:3–12
    [Google Scholar]
  4. Levine M M. Prospects for vaccines. The Magazine of World Health Organization 1986April24–26
    [Google Scholar]
  5. Kaper J B, Lockman H A, Baldini M M, Levine M M. Recombinant nontoxigenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature 1984; 308:655–658
    [Google Scholar]
  6. Saha S, Sanyal S C. Cholera toxin gene-positive Vibrio cholerae Ol Ogawa and Inaba strains produce the new cholera toxin (FEM 03161). FEMS Microbiol Lett 1988; 50:113–116
    [Google Scholar]
  7. Saha S, Sanyal S C. Immunobiological relationships among new cholera toxins produced by CT gene-negative strains of Vibrio cholerae Ol. J Med Microbiol 1989; 28:33–37
    [Google Scholar]
  8. Finkelstein R A, Lospalluto J J. Production of highly purified choleragen and choleragenoid. J. Infect Dis 1970; 121: Suppl: s63–s72
    [Google Scholar]
  9. Lowry O H, Rosebrough N J, Farr A L, Randall R J. Protein measurement with the folin phenol reagent. J BiolChem 1951; 193:265–275
    [Google Scholar]
  10. Dubey R S, Sanyal S C. Characterisation and neutralisation of Aeromonas hydrophila enterotoxin in the rabbit ileal loop model. J Med Microbiol 1979; 12:345–354
    [Google Scholar]
  11. Saha S, Sanyal S C. Neutralisation of the new cholera toxin by antiserum against crude enterotoxin of cholera toxin gene-positive Vibrio cholerae 01 in rabbit ileal loop model. Indian J Med Res 1989; 89:117–120
    [Google Scholar]
  12. Svennerholm A M, Jertbom M, Gothefors L, Karim A M M M, Sack D A, Holmgren J. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit whole cell vaccine. J Infect Dis 1984; 149:884–893
    [Google Scholar]
  13. Lycke N, Holmgren J. Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer’s patches in mice 2 years after oral immunization with cholera toxin. Scand J Immunol 1986; 23:611–616
    [Google Scholar]
  14. Holmgren J, Svennerholm A M, Clements J D, Sack D, Black R, Levine M. An oral B subunit whole cell vaccine against cholera: from concept to successful field trial. In: Mestecky J. (ed) Recent advances in mucosal immunology, part B: effector functions (Advances in Experimental Medicine and Biology 216) New York: Plenum Press; 19871649–1660
    [Google Scholar]
  15. Levine M M, Kaper J B, Herrington D et al. Safety, immunogenicity and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103 HgR. Lancet 1988; 2:467–470
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/00222615-32-1-33
Loading
/content/journal/jmm/10.1099/00222615-32-1-33
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error